A Phase 1, double blind, sponsor open, single and multiple ascending dose study to evaluate
safety, tolerability and pharmacokinetics of PF-07321332 in healthy participants.
Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
Recruiting
Pfizer
Phase 1
This is a Phase 1, non-randomized, open-label, 2-part study to investigate the effect of
renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose
of PF-07321332 in combination with the PK boosting agent ritonavir. Participants will be
selected and categorized into normal renal function or renal impairment groups based on their
estimated glomerular filtration rate. Part 1: will be conducted in approximately 24
participants (approximately 8 per group) with stable mild or moderate renal impairment and a
control group of participants with normal renal function. Part 2 will be conducted in
approximately 8 participants with stable severe renal impairment.
A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19
Recruiting
Pfizer
Phase 3
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective
for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital,
but are at an increased risk of developing severe illness. Throughout the study period,
provision will be made to allow study visits to be conducted at a participant's home or
another non-clinic location if available. The total study duration is up to 24 weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
